| 1. |
Deyell MW, AbdelWahab A, Angaran P, <italic>et al</italic>. 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society position statement on the management of ventricular tachycardia and fibrillation in patients with structural heart disease. Can J Cardiol, 2020, 36(6): 822-836.
|
| 2. |
Chatzidou S, Kontogiannis C, Tsilimigras DI, <italic>et al</italic>. Propranolol versus metoprolol for treatment of electrical storm in patients with implantable cardioverter-defibrillator. J Am Coll Cardiol, 2018, 71(17): 1897-1906.
|
| 3. |
Pedersen SS, van den Broek KC, Erdman RA, <italic>et al</italic>. Pre-implantation implantable cardioverter defibrillator concerns and type D personality increase the risk of mortality in patients with an implantable cardioverter defibrillator. Europace, 2010, 12(10): 1446-1452.
|
| 4. |
Perini AP, Kutyifa V, Veazie P, <italic>et al</italic>. Effects of implantable cardioverter/defibrillator shock and antitachycardia pacing on anxiety and quality of life: A MADIT-RIT substudy. Am Heart J, 2017, 189: 75-84.
|
| 5. |
Thylén I, Moser DK, Str?mberg A, <italic>et al</italic>. Concerns about implantable cardioverter-defibrillator shocks mediate the relationship between actual shocks and psychological distress. Europace, 2016, 18(6): 828-835.
|
| 6. |
Ellison KE, Hafley GE, Hickey K, <italic>et al</italic>. Effect of beta-blocking therapy on outcome in the multicenter unsustained tachycardia trial (MUSTT). Circulation, 2002, 106(21): 2694-2699.
|
| 7. |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERITHF). Lancet, 1999, 353: 2001-2007.
|
| 8. |
Levine JH, Mellits ED, Baumgardner RA, <italic>et al</italic>. Predictors of first discharge and subsequent survival in patients with automatic implantable cardioverter-defibrillators. Circulation, 1991, 84(2): 558-566.
|
| 9. |
Deftereos S, Giannopoulos G, Kossyvakis C, <italic>et al</italic>. Relation of ventricular tachycardia/fibrillation to beta-blocker dose maximization guided by pacing mode analysis in nonpacemaker-dependent patients with implantable cardioverter-defibrillator. Am J Cardiol, 2011, 107(12): 1812-1817.
|
| 10. |
Connolly SJ, Dorian P, Roberts RS, <italic>et al</italic>. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: The OPTIC Study: A randomized trial. JAMA, 2006, 295(2): 165-171.
|
| 11. |
Pacifico A, Hohnloser SH, Williams JH, <italic>et al</italic>. Prevention of implantable-defibrillator shocks by treatment with sotalol. d, l-sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med, 1999, 340(24): 1855-1862.
|
| 12. |
Waldo AL, Camm AJ, deRuyter H, <italic>et al</italic>. Effect of D-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD investigators. survival with oral d-sotalol. Lancet, 1996, 348(9019): 7-12.
|
| 13. |
Gao D, Van Herendael H, Alshengeiti L, <italic>et al</italic>. Mexiletine as an adjunctive therapy to amiodarone reduces the frequency of ventricular tachyarrhythmia events in patients with an implantable defibrillator. J Cardiovasc Pharmacol, 2013, 62(2): 199-204.
|
| 14. |
Hoffmann A, Follath F, Burckhardt D. Safe treatment of resistant ventricular arrhythmias with a combination of amiodarone and quinidine or mexiletine. Lancet, 1983, 1(8326 Pt 1): 704-705.
|
| 15. |
Deyell MW, Steinberg C, Doucette S, <italic>et al</italic>. Mexiletine or catheter ablation after amiodarone failure in the VANISH trial. J Cardiovasc Electrophysiol, 2018, 29(4): 603-608.
|
| 16. |
International mexiletine and placebo antiarrhythmic coronary trial: Ⅰ. Report on arrhythmia and other findings. Impact Research Group. J Am Coll Cardiol, 1984, 4: 1148-163.
|
| 17. |
Pinter A, Akhtari S, O'Connell T, <italic>et al</italic>. Efficacy and safety of dofetilide in the treatment of frequent ventricular tachyarrhythmias after amiodarone intolerance or failure. J Am Coll Cardiol, 2011, 57(3): 380-381.
|
| 18. |
Baquero GA, Banchs JE, Depalma S, <italic>et al</italic>. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies. J Cardiovasc Electrophysiol, 2012, 23(3): 296-301.
|
| 19. |
Kuck KH, Schaumann A, Eckardt L, <italic>et al</italic>. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): A multicentre randomised controlled trial. Lancet, 2010, 375(9708): 31-40.
|
| 20. |
Callans DJ, Zado E, Sarter BH, <italic>et al</italic>. Efficacy of radiofrequency catheter ablation for ventricular tachycardia in healed myocardial infarction. Am J Cardiol, 1998, 82(4): 429-432.
|
| 21. |
Di Biase L, Burkhardt JD, Lakkireddy D, <italic>et al</italic>. Ablation of stable VTs versus substrate ablation in ischemic cardiomyopathy: The VISTA randomized multicenter trial. J Am Coll Cardiol, 2015, 66(25): 2872-2882.
|
| 22. |
Proietti R, Essebag V, Beardsall J, <italic>et al</italic>. Substrate-guided ablation of haemodynamically tolerated and untolerated ventricular tachycardia in patients with structural heart disease: effect of cardiomyopathy type and acute success on long-term outcome. Europace, 2015, 17(3): 461-467.
|
| 23. |
Sosa E, Scanavacca M, d'Avila A, <italic>et al</italic>. Nonsurgical transthoracic epicardial catheter ablation to treat recurrent ventricular tachycardia occurring late after myocardial infarction. J Am Coll Cardiol, 2000, 35(6): 1442-1449.
|
| 24. |
Schmidt B, Chun KR, Baensch D, <italic>et al</italic>. Catheter ablation for ventricular tachycardia after failed endocardial ablation: epicardial substrate or inappropriate endocardial ablation? Heart Rhythm, 2010, 7(12): 1746-1752.
|
| 25. |
Garcia FC, Bazan V, Zado ES, <italic>et al</italic>. Epicardial substrate and outcome with epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation, 2009, 120(5): 366-375.
|
| 26. |
Pokushalov E, Romanov A, Turov A, <italic>et al</italic>. Percutaneous epicardial ablation of ventricular tachycardia after failure of endocardial approach in the pediatric population with arrhythmogenic right ventricular dysplasia. Heart Rhythm, 2010, 7(10): 1406-1410.
|
| 27. |
Koruth JS, Dukkipati S, Miller MA, <italic>et al</italic>. Bipolar irrigated radiofrequency ablation: a therapeutic option for refractory intramural atrial and ventricular tachycardia circuits. Heart Rhythm, 2012, 9(12): 1932-1941.
|
| 28. |
Robinson CG, Samson PP, Moore KMS, <italic>et al</italic>. Phase Ⅰ/Ⅱ trial of electrophysiology-guided noninvasive cardiac radioablation for ventricular tachycardia. Circulation, 2019, 139(3): 313-321.
|
| 29. |
Sacher F, Sobieszczyk P, Tedrow U, <italic>et al</italic>. Transcoronary ethanol ventricular tachycardia ablation in the modern electrophysiology era. Heart Rhythm, 2008, 5(1): 62-68.
|
| 30. |
Sapp JL, Beeckler C, Pike R, <italic>et al</italic>. Initial human feasibility of infusion needle catheter ablation for refractory ventricular tachycardia. Circulation, 2013, 128(21): 2289-2295.
|
| 31. |
Vaseghi M, Barwad P, Malavassi Corrales FJ, <italic>et al</italic>. Cardiac sympathetic denervation for refractory ventricular arrhythmias. J Am Coll Cardiol, 2017, 69(25): 3070-3080.
|
